An immunotherapy drug combination could prolong the lives of individuals diagnosed with advanced non-small cell lung cancer, revealed research.
People diagnosed with advanced non-small cell lung cancer have limited treatment options. Therapies for the disease have improved over the past five years, including advances in immunotherapy, although resistance develops in most tumors even after initial tumor response.
"This clinical trial shows promise in extending the lives of patients who ...
↧